Stephens & Co. Reiterates Overweight on NextGen Healthcare, Maintains $24 Price Target
Portfolio Pulse from richadhand@benzinga.com
Stephens & Co. analyst Jeff Garro has reiterated an Overweight rating on NextGen Healthcare (NASDAQ:NXGN) and maintained a $24 price target.
July 25, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NextGen Healthcare's stock rating has been reiterated as Overweight by Stephens & Co. with a maintained price target of $24.
The reiteration of an Overweight rating by a reputable analyst suggests a positive outlook for the company's stock. The maintained price target of $24 indicates that the analyst believes the stock is still undervalued, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100